Cargando…
Novel myostatin-specific antibody enhances muscle strength in muscle disease models
Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes the potential of myostatin-targete...
Autores principales: | Muramatsu, Hiroyasu, Kuramochi, Taichi, Katada, Hitoshi, Ueyama, Atsunori, Ruike, Yoshinao, Ohmine, Ken, Shida-Kawazoe, Meiri, Miyano-Nishizawa, Rie, Shimizu, Yuichiro, Okuda, Momoko, Hori, Yuji, Hayashi, Madoka, Haraya, Kenta, Ban, Nobuhiro, Nonaka, Tatsuya, Honda, Masaki, Kitamura, Hidetomo, Hattori, Kunihiro, Kitazawa, Takehisa, Igawa, Tomoyuki, Kawabe, Yoshiki, Nezu, Junichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835227/ https://www.ncbi.nlm.nih.gov/pubmed/33495503 http://dx.doi.org/10.1038/s41598-021-81669-8 |
Ejemplares similares
-
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
por: Sampei, Zenjiro, et al.
Publicado: (2018) -
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
por: Mimoto, Futa, et al.
Publicado: (2013) -
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
por: Fukuzawa, Taku, et al.
Publicado: (2017) -
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering
por: Hori, Yuji, et al.
Publicado: (2022) -
Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro
por: Noguchi-Sasaki, Mariko, et al.
Publicado: (2018)